Skip to content

Multisensory Rehabilitation of Hemianopia

Non-Invasive Multisensory Rehabilitation of Hemianopia

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04963075
Enrollment
5
Registered
2021-07-15
Start date
2021-09-22
Completion date
2025-09-30
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemianopia

Keywords

visual cortex injury, stroke, blindness, cortical damage

Brief summary

The current proposal is to generate "proof of concept" evidence that hemianopia can be successfully rehabilitated in humans when this multisensory rehabilitation paradigm is used.

Detailed description

The over-arching objective is to evaluate the functional recovery of vision in hemianopic patients engaged with a multisensory training paradigm. Unilaterally blind participants will participate in weekly training sessions in which they are exposed to high-density spatiotemporally congruent and consistent visual-auditory stimulation. The participants will be tested on a battery of visual tasks probing different levels of function in different environments in a longitudinal study to track recovery.

Interventions

DEVICEmultisensory rehabilitation paradigm

In initial ("training") sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between "training/testing" and "testing only" sessions in which performance on the visual battery will be re-assessed.

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER
Neuroscience Clinical Trial and Innovation Center (NCTIC)
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Subjects will participate in weekly sessions (1.5-2 hours) for three months which contain baseline testing, training, and repeated testing of visual recovery

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* adults (\<85) of either sex * diagnosis of a stable homonymous hemianopia (\>6 months) with absence of hemineglect * lesion encompassing at least primary visual cortex but sparing parietal cortex * normal auditory and cognitive function * willingness to participate in the three month program * ability to perform the visual discriminations in their intact field

Exclusion criteria

* adults (\>85) * normal auditory and cognitive function * unwilling to participate in the three month program * inability to perform the visual discriminations in their intact field

Design outcomes

Primary

MeasureTime frameDescription
Number of Points Detected at Multiple LocationsMonth 3To assess recovery of function - number of detected visual points in both hemifields (discrete count variable, higher values are "better") - Visual fields are divided into "affected" areas of the field (detection \< 50% on initial testing) and "intact" areas of the field (detection \> 50% on initial testing), aggregate data are reported for each at the start and end of study

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBenjamin Rowland, PhD

Wake Forest Health Sciences

Baseline characteristics

Characteristic
Age, Continuous67.6 years
STANDARD_DEVIATION 3.5
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
4 Participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 5
other
Total, other adverse events
0 / 5
serious
Total, serious adverse events
0 / 5

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026